{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=27",
    "query": {
      "condition": "Recurrent Ovary Cancer",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 765,
    "total_pages": 77,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T15:06:24.625Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00137865",
      "title": "Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "EGEN-001 (phIL-12-005/PPC)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "EGEN, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2005-08",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00137865"
    },
    {
      "nct_id": "NCT02855944",
      "title": "ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 349,
      "start_date": "2017-03-01",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Augusta, Georgia",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02855944"
    },
    {
      "nct_id": "NCT03323398",
      "title": "Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Solid Tumor Malignancies or Lymphoma",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "mRNA-2416",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2017-08-15",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03323398"
    },
    {
      "nct_id": "NCT00275028",
      "title": "AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Recurrent Ovarian Epithelial Cancer",
        "Stage I Ovarian Epithelial Cancer",
        "Stage II Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "cediranib maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2005-10",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-11-09",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00275028"
    },
    {
      "nct_id": "NCT06028932",
      "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-08",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06028932"
    },
    {
      "nct_id": "NCT03585764",
      "title": "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "MOv19-BBz CAR T cells",
          "type": "DRUG"
        },
        {
          "name": "Alpha Folate Receptor expression test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2018-10-24",
      "completion_date": "2024-03-26",
      "has_results": true,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585764"
    },
    {
      "nct_id": "NCT00748657",
      "title": "Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Ovarian Epithelial Tumor",
        "Ovarian Granulosa Cell Tumor",
        "Ovarian Gynandroblastoma",
        "Ovarian Sertoli-Leydig Cell Tumor",
        "Ovarian Sex Cord Tumor With Annular Tubules",
        "Ovarian Sex Cord-Stromal Tumor",
        "Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types",
        "Ovarian Steroid Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2008-09-22",
      "completion_date": "2013-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 36,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 24 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00748657"
    },
    {
      "nct_id": "NCT02312245",
      "title": "Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2015-07-21",
      "completion_date": "2023-04-24",
      "has_results": true,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312245"
    },
    {
      "nct_id": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "NSCLC",
        "Non Small Cell Lung Cancer",
        "NSCLC, Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "Pancreas Cancer",
        "Pancreatic Neoplasm",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colon Cancer",
        "Rectal Cancer",
        "Cancer",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Ovary Cancer",
        "Lung Cancer",
        "MESOM"
      ],
      "interventions": [
        {
          "name": "A2B694",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A2B543",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT CDx with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2024-04-03",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06051695"
    },
    {
      "nct_id": "NCT01535157",
      "title": "Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Cancer of Ovary",
        "Cancer of the Ovary",
        "Ovary Neoplasms",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fenretinide/LXS + Ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "South Plains Oncology Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2012-02",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2020-08-27",
      "last_synced_at": "2026-10-30T15:06:24.625Z",
      "location_count": 3,
      "location_summary": "Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01535157"
    }
  ]
}